New York’s leading experts in Alzheimer’s disease (AD) and dementia care, formerly known as the Alzheimer’s Association, New…
Articles by Ana de Barros, PhD
Takeda Pharmaceutical Company and partner Zinfandel Pharmaceuticals announced the completion of patient enrollment in the TOMMORROW Phase 3 Clinical…
A critical but vulnerable brain region seems to be the first area disturbed by late onset Alzheimer’s disease, and to…
Scientists have discovered the anti-cancer drug bexarotene may target the first step in the toxic chain activity that leads to the…
As part of Allianz Championship week in Boca Raton, Florida, Allianz encouraged golf enthusiasts to share their favorite golf memories on Facebook, Twitter,…
Tarrytown, New York-based PsychoGenics has announced its Line-41 mouse model of Alzheimer’s disease (AD) has obtained a license from the…
A National Football League broadcaster and former NFL player is urging Americans to “Huddle Up for New Alzheimer’s Treatments” by participating…
Lack of sleep on a regular basis or waking up several times during the night may be harmful to the brain…
PsychoGenics Inc. and the Alzheimer’s Drug Discovery Foundation (ADDF) announced a collaboration that opens PsychoGenics’ Alzheimer’s animal models and investigational…
Evotec AG has reached an important milestone concerning its TargetAD partnership with Janssen Pharmaceuticals for the transition of a product into further drug…